TELA TELA Bio, Inc. Insider Trading

EW Healthcare Partners Fund 2 acquires 3,604,000 shares (+87.7%) at $1.11; firm now holds 7,714,709 shares amid -25.5% month & -$8.6M net income.

EW Healthcare Partners Fund 2, a 10% owner, purchased 3,604,000 shares at $1.11 on 2025-11-17, boosting its stake by 87.7% to 7,714,709 shares total for $4,000,440.00. This substantially increased commitment occurs as the stock has declined 25.5% over 30 days and 34.5% over 90 days, trading at $1.14 against a 52-week high of $3.14. The company reported $20,689,000 in revenue for the latest quarter with a net loss of $8,603,000, underscoring continued unprofitability despite 18.6% annual revenue growth. The scale of this accumulation—nearly doubling a major stakeholder's position—warrants attention to whether the fund's conviction in TELA's turnaround thesis has strengthened, or whether capital availability and pricing flexibility are driving the acquisition strategy.

CEO Antony Koblish bought 88,888 shares of TELA at $2.25 on 2024-10-24; stock now -66.1% from 52-week high amid cluster buying by 3 other insiders.

Antony Koblish, TELA's Chief Executive Officer, purchased 88,888 shares for $199,998.00 at $2.25, increasing his holdings by 24.0% to 458,897 shares post-transaction. This buy occurs while the stock trades 66.1% below its 52-week high of $7.61, and coincides with 3 other insiders buying within the past 14 days—a multi-insider cluster pattern. While the company is unprofitable with a $-12,600,000.00 net loss in the latest quarter, it has shown +41.1% annual revenue growth and maintains a $63,761,598.84 market cap. The CEO's cross-ticker track record shows 100.00% win rate on prior buys with +64.2% average 90-day returns, and his single prior TELA buy on 2023-11-14 was well-timed (+64.2% in 90 days), suggesting a pattern of purchases positioned ahead of recoveries. The concurrent buying activity by multiple insiders and the CEO's significant stake increase warrant close monitoring of execution against the company's path to profitability.

Chief Commercial Officer bought 6,666 shares (6.7K) of TELA at $2.25; cluster buy by 3+ insiders within 14 days, positive prior timing at this ticker.

Firestone Gregory A., Chief Commercial Officer of TELA Bio, purchased 6,666 shares for $14,998.50 on 2024-10-24, increasing his stake by 13.2% to 57,279 shares. This transaction occurs as part of a broader cluster pattern with 3 other insiders also buying within the past 14 days, signaling coordinated confidence at a depressed price point. His prior buy at TELA on 2023-12-05 demonstrated strong timing, delivering +19.8% 30-day and +22.8% 90-day returns, and his cross-ticker track record shows 1 prior buy with 100% 90-day win rate at +22.8% average return. The company is unprofitable with $-12.6M net income in the latest quarter and declining price momentum (-43.9% over 90 days, -66.1% from 52-week high), placing the buy at a materially lower valuation than the $7.61 52-week peak—context that aligns with the timing pattern observed in his prior transaction.

TELA CTO Talmo Paul buys 22,222 shares at $2.25; 4-insider cluster buy in 14 days; stock -66.1% from 52-week high.

Talmo Paul, Chief Technology Officer of TELA Bio, purchased 22,222 shares at $2.25, increasing his holdings by 32.3% to 91,082 shares total. This transaction is part of a cluster pattern in which 3 other insiders also bought within the past 14 days, suggesting coordinated or parallel conviction at depressed valuations. The stock is currently down 66.1% from its 52-week high of $7.61, though it has recovered 11.2% over the past 30 days. The company posted a net loss of $-12,600,000.00 in its latest quarter on revenue of $16,091,000.00, with full-year profitability negative; however, annual revenue growth of 41.1% indicates ongoing operational expansion despite losses. The multi-insider buy cluster during a substantial drawdown from recent highs warrants examination of whether this reflects informed expectation of stabilization or recovery.

TELA COO/CFO Cuca Roberto bought 64,444 shares at $2.25 on 2024-10-24; stock -66.1% from 52-week high, cluster buy by 3 other insiders within 14 days.

Cuca Roberto, serving as both COO and CFO, purchased 64,444 shares for $144,999.00, increasing his holdings by 70.9% from 90,944 to 155,388 shares. This open-market buy occurs at $2.25, substantially below the 52-week high of $7.61, while the company faces structural profitability challenges: latest quarter revenues were $16,091,000.00 with net income of $-12,600,000.00, and full-year results were unprofitable. The timing aligns with a cluster pattern—3 other insiders also bought within the past 14 days—suggesting coordinated management assessment. Notably, Roberto's prior buy at TELA on 2023-11-14 was well-timed at the 90-day mark (posting +66.0% return), and his cross-ticker track record shows 1 prior buy with 100% win rate on the 90-day horizon, though current price performance shows the stock down 43.9% over the past 90 days.

10% owner ORBIMED ADVISORS LLC sold 428,300 shares in 3 transactions (Jun 28–Jul 2) for blended avg $4.72; stock down 56.8% from 52-week high

ORBIMED ADVISORS LLC, holding 2.41M shares post-transaction, conducted 3 separate sales totaling 428,300 shares for $2,022,000.00 between June 28 and July 2, 2024, representing a 15.1% reduction in the holder's position. The sales occurred at prices ranging from $4.54 to $4.74 (blended average $4.72), while the stock currently trades at $4.61—down 56.8% from its 52-week high of $10.68 and down 16.6% over the past 30 days. TELA is unprofitable (latest quarter net income: $-5.7M) despite 41.1% annual revenue growth, creating a pattern of early-stage biotech cash burn that may be driving capital raise pressures or portfolio rebalancing decisions. The holder's prior cross-ticker sales record shows a 0.00% well-timed rate (all 11 prior sells were followed by positive average 90-day returns), suggesting this holder's historical sells have not been prospectively accurate market calls.